AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Quarter Return
-2.91%
1 Year Return
+18.84%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$136M
AUM Growth
+$136M
(-18%)
Cap. Flow
-$37.2M
Cap. Flow
% of AUM
-27.37%
Top 10 Holdings %
Top 10 Hldgs %
25.49%
Holding
262
New
34
Increased
55
Reduced
87
Closed
45
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
$1.14M |
| 2 |
Invesco QQQ Trust
QQQ
|
$1.02M |
| 3 |
Invesco NASDAQ 100 ETF
QQQM
|
$1.02M |
| 4 |
Amphastar Pharmaceuticals
AMPH
|
$1M |
| 5 |
Enovis
ENOV
|
$904K |
Top Sells
| 1 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$2.31M |
| 2 |
UroGen Pharma
URGN
|
$2.16M |
| 3 |
Corcept Therapeutics
CORT
|
$2.14M |
| 4 |
KalVista Pharmaceuticals
KALV
|
$1.5M |
| 5 |
Axsome Therapeutics
AXSM
|
$1.41M |
Sector Composition
| 1 | Healthcare | 60.25% |
| 2 | Real Estate | 12.98% |
| 3 | Financials | 6.42% |
| 4 | Industrials | 2.59% |
| 5 | Technology | 2.57% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Intuitive Surgical
ISRG
$158B
| $890K | 0.66% |
2,000
-1,000
| -33% | -$445K |
|
52
Viking Therapeutics
VKTX
$3.02B
| $875K | 0.64% |
16,500
-1,500
| -8% | -$79.5K |
|
53
Protagonist Therapeutics
PTGX
$3.62B
| $866K | 0.64% |
25,000
| – | – |
|
54
Sanofi
SNY
$122B
| $849K | 0.63% |
17,500
+2,500
| +17% | +$121K |
|
55
Perspective Therapeutics
CATX
$251M
| $818K | 0.6% |
82,000
-93,676
| -53% | -$934K |
|
|
VRNA
56
Verona Pharma
VRNA
$9.18B
| $810K | 0.6% |
56,000
| – | – |
|
57
AGNC Investment
AGNC
$10.4B
| $808K | 0.59% |
84,646
| – | – |
|
58
NVIDIA
NVDA
$4.15T
| $742K | 0.55% |
6,009
+5,329
| +784% | +$658K |
|
|
NARI
59
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $722K | 0.53% |
15,000
-48,000
| -76% | -$2.31M |
|
60
Embecta
EMBC
$837M
| $706K | 0.52% |
56,500
-55,000
| -49% | -$688K |
|
61
Dyne Therapeutics
DYN
$1.92B
| $706K | 0.52% |
20,000
| – | – |
|
62
Symbotic
SYM
$5.06B
| $703K | 0.52% |
20,000
-5,000
| -20% | -$176K |
|
|
VALN
63
Valneva
VALN
$746M
| $649K | 0.48% |
88,252
+26,248
| +42% | +$193K |
|
64
Accuray
ARAY
$165M
| $637K | 0.47% |
350,000
| – | – |
|
65
Sagimet Biosciences
SGMT
$239M
| $633K | 0.47% |
185,000
| – | – |
|
|
RVNC
66
DELISTED
Revance Therapeutics, Inc.
RVNC
| $630K | 0.46% |
245,000
| – | – |
|
|
ONIT
67
Onity Group Inc.
ONIT
$339M
| $613K | 0.45% |
25,567
| – | – |
|
68
VYNE Therapeutics
VYNE
$8.09M
| $612K | 0.45% |
310,500
-134,500
| -30% | -$265K |
|
69
Procept Biorobotics
PRCT
$2.11B
| $611K | 0.45% |
10,000
-15,000
| -60% | -$916K |
|
70
SoundHound AI
SOUN
$5.19B
| $593K | 0.44% |
150,000
-50,000
| -25% | -$198K |
|
71
AeroVironment
AVAV
$11.9B
| $574K | 0.42% |
3,150
-4,850
| -61% | -$883K |
|
72
iShares 1-3 Year Treasury Bond ETF
SHY
$24.5B
| $573K | 0.42% |
7,016
+1,558
| +29% | +$127K |
|
73
Cabaletta Bio
CABA
$144M
| $524K | 0.39% |
70,000
+5,000
| +8% | +$37.4K |
|
74
JPMorgan BetaBuilders Japan ETF
BBJP
$13.7B
| $487K | 0.36% |
8,623
-124
| -1% | -$7K |
|
75
iShares MSCI Australia ETF
EWA
$1.51B
| $485K | 0.36% |
19,853
-841
| -4% | -$20.5K |
|